Credit Suisse Ag Immunity Bio, Inc. Call Options Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IBRX
# of Institutions
191Shares Held
66.7MCall Options Held
2.27MPut Options Held
3.23M-
State Street Corp Boston, MA14.2MShares$87.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.5MShares$83.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.4MShares$64.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.48MShares$21.5 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY1.44MShares$8.87 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $2.47B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...